Drug Trial Radar · NCT00284856
Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)
Last checked: Nov 19, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,640
Actual
Start
May 2006
Primary completion
Apr 2010
Study completion Apr 2010
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Feb 1, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter study to evaluate the efficacy and safety of MK0476 versus placebo in participants with chronic asthma who actively smoke cigarettes.
Conditions
- Asthma
Interventions
montelukast sodiumDrug
montelukast 10 mg tablet once daily, 6 month treatment period
Comparator: PlaceboDrug
fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
Comparator: fluticasoneDrug
fluticasone propionate 250 mcg twice daily, 6 month treatment period
Comparator: PlaceboDrug
montelukast 10 mg Pbo tablet once daily, 6 month treatment period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Asthma-control Days Over the 6-month Treatment PeriodTime frame: 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.